iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research

Rhea-AI Summary

iSpecimen Inc. partners with TriMetis Life Sciences to enhance quality control and assurance through digital AI histopathology services. The partnership aims to revolutionize tissue assessment for preclinical research by utilizing AI-powered solutions to standardize and enhance tissue sample evaluation, focusing on solid tumor types. This initiative will integrate technology solutions from TriMetis into iSpecimen's platform, providing researchers and suppliers access to critical data and AI-enhanced information. The partnership seeks to streamline procurement processes, increase accuracy, and reduce delays, ultimately cutting costs and delivering better outcomes for patients worldwide.

Insights

Medical Research Analyst

The collaboration between iSpecimen and TriMetis introduces a significant technological advancement in the field of histopathology, particularly in the standardization and quality assurance of tissue-based oncology samples. The adoption of AI-powered digital pathology solutions, such as TriMetis' Computer-Assisted Pathology (TCAP) Quality Control AI, represents a paradigm shift in how tissue samples are evaluated for research purposes.

From a medical research perspective, the integration of TCAP AI into iSpecimen's marketplace could lead to more accurate and reproducible results, which is crucial for the validation of clinical findings and the development of new treatments. The use of Immunohistochemical (IHC) Methods and Fluorescent in Situ Hybridization (FISH) assessments, enhanced by AI, will likely improve the comprehensiveness of cancer tissue analyses, potentially accelerating the pace of cancer research and drug development. This could have a considerable impact on the biotechnology and pharmaceutical sectors, where the quality and reliability of preclinical research are foundational to the success of clinical trials.

Healthcare IT Specialist

The partnership between iSpecimen and TriMetis underscores the growing importance of digital transformation in the healthcare industry. The integration of AI and digital workflows into the histopathology process is expected to streamline procurement processes and reduce the risk of errors associated with manual tissue assessment. This efficiency gain could translate into cost savings for healthcare providers and research institutions, as well as a reduction in time-to-market for new medical discoveries.

Moreover, the ARCH Ecosystem, which includes the ARCH Marketplace and ARCH LabFlow, is a noteworthy innovation in the management of digital images, biospecimens and associated data. This ecosystem is designed to facilitate end-to-end management, which is likely to enhance the operational efficiency of laboratories and research institutions. This operational efficiency could have long-term financial implications for stakeholders, potentially making iSpecimen's platform more attractive to researchers and suppliers, thereby increasing the company's market share in the digital pathology space.

Market Research Analyst

The strategic partnership between iSpecimen and TriMetis could have a notable impact on the competitive landscape of the biospecimen supply market. By combining their respective strengths, iSpecimen's global network and TriMetis' AI technologies, the collaboration is positioned to set new industry-wide benchmarks for tissue sample quality assessments.

From a market perspective, this initiative could lead to a transformative shift in customer expectations regarding sample quality and service delivery. As the partnership aims to revolutionize tissue assessment for preclinical research, other market players may be compelled to adopt similar AI-driven approaches or risk falling behind. This could drive innovation and competition within the industry, potentially benefiting consumers through improved services and possibly leading to a consolidation of market players around new technological standards.

Partnership Aims to Optimize Quality Control and Assurance Through Digital AI Histopathology Services

LEXINGTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it entered into a pilot program agreement with TriMetis Life Sciences, LLC (“TriMetis”), a provider of digital pathology, laboratory and AI workflow and automation solutions for hospitals, pathology, diagnostic and pharmaceutical companies. This agreement aims to establish a strategic partnership between iSpecimen and TriMetis, providing opportunities for iSpecimen, its suppliers and customers to utilize technology solutions from TriMetis.

By combining iSpecimen’s global network of suppliers and researchers with TriMetis’ AI-powered, automated digital pathology solutions, this partnership is working to address industry challenges, reduce the risk of errors associated with manual processes and revolutionize tissue assessment for preclinical research.

Focusing initially on a substantial subset of solid tumor types utilizing TriMetis’ Computer-Assisted Pathology (TCAP) Quality Control AI, the partnership will help standardize and enhance tissue sample evaluation. This initiative will make significant strides in the comprehensive analysis of cancer tissues through the integration of Immunohistochemical (“IHC”) Methods and Fluorescent in Situ Hybridization (“FISH”) assessments. This is accomplished by providing researchers and suppliers access to TriMetis’ ARCH Ecosystem, including the ARCH Marketplace and ARCH LabFlow for end-to-end management of digital images, biospecimens, associated data and AI-enhanced information via the integration of TriMetis’ solutions into iSpecimen’s platform. The data and these visuals are crucial for researchers to make informed decisions, ensuring they choose the samples that fit their specific research needs.

“This pilot program exemplifies the fusion of two online portals, leveraging cutting-edge technological tools to both enhance customer service and elevate industry standards,” said Tracy Curley, Chief Executive Officer of iSpecimen. Ms. Curley continued, “For both iSpecimen and TriMetis, the focus is first and foremost on establishing best practices for quality control and assurance. By incorporating AI readings and images, our goal is to enhance the standardization of tissue-based oncology samples on the iSpecimen Marketplace®, contributing to a transformative shift in the quality assessments of tissue samples. Our collaboration with TriMetis represents a milestone in advancing tissue research quality, streamlining procurement processes and setting new industry-wide benchmarks through this innovative process that will further increase accuracy.”

Phil Cestaro, Chief Executive Officer of TriMetis Life Sciences, commented on the partnership, stating, “At TriMetis, we are committed to advancing cancer research through software solutions and cutting-edge AI technologies for laboratories, researchers, and biospecimen providers. Our ARCH software solutions and TCAP AI reduce the time and cost of research by providing critical data and eliminating returns to ensure researchers get the samples they need. We strongly believe that through partnerships like this, we can deliver better outcomes for patients all over the world.” Mr. Cestaro continued, “TriMetis’ TCAP AI and image management capabilities, combined with iSpecimen’s platform, is a significant step towards revolutionizing tissue-based research. Our AI-driven approach not only benefits iSpecimen’s suppliers by increasing efficiency but also enhances the overall opportunity for client success. This innovative partnership illustrates how two potentially competitive platforms can work together for the benefit of their clients and customers.”

“The synergy between iSpecimen and TriMetis addresses a significant issue in tissue-based research, acknowledging that pathologists are pressed to concentrate on patient-related concerns, often sidelining the depth of analysis required for research,” added Eric Langlois, Chief Revenue Officer of iSpecimen. Mr. Langlois continued, “Often, examining tissue samples for research is deferred until specifically requested, causing obstacles and delays. This partnership will focus on simplifying and standardizing these processes by utilizing TriMetis’ digital AI services and tapping into iSpecimen’s global network. By making the pathology review process more efficient and introducing a fully-pathology-reviewed inventory, we are aiming to reduce delays, improve efficiency and ultimately cut costs. I am confident that this partnership will bring significant benefits to both researchers and suppliers.”

About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

About TriMetis
Established in 2012, TriMetis Life Sciences, LLC. is a pioneering tissue technology company founded by scientists with decades of extensive experience in biospecimen procurement, clinical trials, and software development. Through the innovative ARCH Ecosystem, TriMetis facilitates access to top-tier biospecimens, AI-driven quality control applications, and automated solutions for laboratory workflows tailored to cancer researchers.

By fully embracing and investing in cutting-edge automation, artificial intelligence, and robotic technologies, TriMetis is propelling a century-old process into the future. Researchers now benefit from enhanced operational efficiency, superior data quality, and streamlined workflows, ultimately leading to improved outcomes across the board. For further insights into TriMetis Life Sciences, please explore www.TriMetisLS.com and follow @TriMetisLS on various social media platforms, including LinkedIn, Instagram, Facebook, and YouTube.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," “believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contacts
KCSA Strategic Communications
Phil Carlson / Erika Kay
iSpecimen@kcsa.com

TriMetis Life Sciences
Investment Opportunities
Phil Cestaro
Info@trimetisls.com

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com

TriMetis Life Sciences
Corporate Communications & Business Development
Kaitlynn Clement / Pete Cestaro
Info@trimetisls.com

FAQ

What is the partnership about between iSpecimen Inc. and TriMetis Life Sciences?

The partnership aims to establish a strategic collaboration to revolutionize tissue assessment for preclinical research using AI-powered solutions.

How will the partnership benefit researchers and suppliers?

The partnership seeks to provide access to critical data and AI-enhanced information, streamline procurement processes, increase accuracy, and reduce delays, ultimately cutting costs and delivering better outcomes for patients worldwide.

What technology solutions from TriMetis will be integrated into iSpecimen's platform?

The partnership will integrate TriMetis' Computer-Assisted Pathology (TCAP) Quality Control AI and ARCH Ecosystem, including the ARCH Marketplace and ARCH LabFlow.

What is the goal of the partnership between iSpecimen and TriMetis?

The goal is to enhance the standardization of tissue-based oncology samples, contributing to a transformative shift in the quality assessments of tissue samples and establishing best practices for quality control and assurance.

How will the partnership address industry challenges?

The partnership aims to reduce the risk of errors associated with manual processes and make significant strides in the comprehensive analysis of cancer tissues through the integration of Immunohistochemical (IHC) Methods and Fluorescent in Situ Hybridization (FISH) assessments.